openPR Logo
Press release

URALCHEM HOLDING P.L.C. Reports IFRS Financial Results for the First Quarter of 2012

06-05-2012 08:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: URALCHEM

URALCHEM HOLDING P.L.C. Reports IFRS Financial Results for

Moscow, Russia – May 31, 2012 -- (For Immediate Release)

- Revenue increased to US $673 million, compared to US $566 million in Q1 2011.
- Operating profit increased to US $178 million, compared with US $160 million in Q1 2011.
- Adjusted EBITDA grew to US $207 million, compared to US $186 million in Q1 2011.
- Net profit amounted to US $354 million, compared with US $174 million in Q1 2011.

URALCHEM HOLDING P.L.C. (hereinafter URALCHEM Holding or the Company), a Cypriot holding company of the URALCHEM Group (hereinafter the Group), one of the largest producers of nitrogen and phosphate fertilizers in Russia, announced its unaudited IFRS financial results for the first quarter of 2012 ending 31 March 2012.

Dmitry Konyaev, CEO of URALCHEM, OJSC (part of the Group), commented on the first quarter of 2012 results, “I am pleased with the Company’s results in the first quarter of this year. We are moving ahead as planned. Net profit in the first quarter of 2012 more than doubled compared to the same period last year. This happened due to the acquisition of Minudobrenia in Perm, as well as the reassessment of our share in the enterprise. Besides, the net profit figure was influenced by a considerable reduction in interest expenses on loans which became possible after we refinanced the loan portfolio last year.”

Financial Results

Revenue for the first quarter of 2012 grew 19% to US $673 million, compared to US $566 million in the first quarter of 2011. Operating profit amounted to US $178 million, or 26% of the revenue, compared with the operating profit of US $160 million, or 28% of the revenue in the first quarter of 2011.

Net profit for the first quarter of 2012 more than doubled, amounting to US $354 million, compared to US $174 million in the first quarter of 2011. Without the reassessment of the Company’s share in Minudobrenia, Perm the net profit growth comprised 15%.

During the first quarter of 2012, adjusted EBITDA reached US $207 million, compared to US $186 million the year before, a rise of 11%. Adjusted EBITDA margin for the first quarter of 2012 comprised 31% of revenue compared with 33% of revenue for the first quarter of 2011.

Markets

In the first quarter of 2012 the prices of fertilizers and intermediates showed significantly different dynamics. Prices for ammonia at the Yuzhny port fell to $70 / t due to low demand, both in agriculture and industry, which coincided with the launch of Qafco V. Market recovery began only in late March.

During January to early February the urea market repeated its dynamics in 2011. However, in mid-February a rapid increase in the price of urea started due to high demand in the U.S. The late Q1/early Q2 price level approached peak figures ??of 2011 even surpassing them at certain markets. Prospects for market development in the second quarter remain optimistic for market participants.

Prices for ammonium nitrate were stable during the first quarter due to high volumes of domestic market shipments.

The global market of phosphate fertilizers in the first quarter of 2012 was characterized by low activity, with prices going down slightly. European demand was limited due to severe weather conditions and financial instability. Moderate recovery in prices occurred in late Q1 due to higher demand in Latin America and the U.S. domestic market.

Sales

In the first quarter of 2012 the Group’s product sales amounted to 1.7 million tons, up 20% compared to the first quarter of 2011. Through the acquisition of OJSC Minudobrenia, Perm in January 2012, sales of urea and of ammonia increased significantly.

Financial Situation

Cash generated from operating activities grew by 4%, from US $167 million in the first quarter of 2011 to US $174 million in the first quarter of 2012.

On 31 March 2012, the Company’s net debt amounted to US $1,076 million. The weighted average interest rate in the loan portfolio for the first quarter 2012 decreased to 5.85% compared to annual 8.0% for the same period last year.

Annex to the press release about the unaudited financial results for the first quarter of 2012

EBITDA is a profit / loss from financial and economic activities during the reporting period, before deduction of income tax on profits, income and interest costs, depreciation and amortization. "Adjusted EBITDA" is EBITDA for the reporting period before goodwill, profit / loss from associates, profit / loss on foreign exchange differences arising on financial performance and profit / loss on operations with derivative financial instruments. Adjusted EBITDA is operating profit before depreciation and amortization and financial results of operations with derivative financial instruments. In accordance with International Financial Reporting Standards ("IFRS"), depreciation and amortization are included in cost structure, and in the selling, general and administrative expenses. IFRS does not require the disclosure and does not describe the calculation of EBITDA and adjusted EBITDA, among other financial indicators, so they can not substitute for net profit for the period when evaluating the results of operations or the measure of cash provided by operating activities when evaluating liquidity. Approach to the calculation of EBITDA and adjusted EBITDA, as described earlier, may not coincide with the approaches used by other companies, therefore, comparability may be limited. We believe that EBITDA and adjusted EBITDA provide useful information to investors because they are indicators of the stability and efficiency of our business and our ability to fund discretionary spending such as capital expenditures, the acquisition of subsidiaries and other investments, as well as indicators of our ability to incur and service debt. IFRS classifies depreciation and amortization to operating costs, while in fact they are distributed to the current period non-cash expenses for the acquisition or creation of fixed assets, incurred in previous periods, and are not affiliated with the movement of funds.

URALCHEM, OJSC is one of the largest producers of nitrogen and phosphate fertilisers in Russia and the CIS with production capacities of over 2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is the second largest ammonium nitrate producer in the world and number one in Russia, the second largest producer of nitrogen fertilisers in Russia. Key production assets of URALCHEM, OJSC include Azot Branch of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm; MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk, Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk, Moscow region.

Media Contact:
PR department
URALCHEM, OJSC
10, Presnenskaya Naberezhnaya
Moscow, Russian Federation, 123317
+7 (495) 721 89 89
pr@uralchem.com
www.uralchem.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release URALCHEM HOLDING P.L.C. Reports IFRS Financial Results for the First Quarter of 2012 here

News-ID: 223905 • Views:

More Releases from URALCHEM

Uralchem Group's humanitarian consignment for Zimbabwe begins its sea journey from the EU
Uralchem Group's humanitarian consignment for Zimbabwe begins its sea journey fr …
Uralchem Group announces that a humanitarian shipment of over 23,000 tonnes of fertilisers for Zimbabwe has been fully loaded onto a vessel in the ports of Riga, Latvia, and Ghent, Belgium, and has started its journey to the port of Beira in Mozambique. From there the fertilisers will be transported to Zimbabwe by land. The shipment, comprising bulk loads of potash and NPKS fertilisers, is again facilitated by the United Nations
Uralchem Held Own Session at Russia-Africa Forum on Ways to Overcome Hunger in A …
Uralchem, one of the key suppliers of Russian mineral fertilisers to Africa, held a session titled 'Stabilizing the Fertiliser Market to Eradicate Hunger in African Countries' as part of the second Russia-Africa Economic and Humanitarian Forum. The session was attended by leaders of countries and regions, heads of Russian and African organisations directly related to food security in Africa: Emmerson Mnangagwa, President of the Republic of Zimbabwe, Kassim Majaliwa Majaliwa, Prime

More Releases for EBITDA

Potential Impact of COVID-19 on: Panoramic X-Ray System Market Development and t …
The Panoramic X-Ray System Market report is intended to function as a supportive means to assess the Panoramic X-Ray System market ( https://bit.ly/3oCjPxR ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the clients in
Coronavirus impact on: Deep Brain Stimulation Systems Market revenues, COGS Anal …
The Deep Brain Stimulation Systems market report provides an in-depth analysis of the global Deep Brain Stimulation Systems market ( https://bit.ly/2TA4AYc ) , comprising the overall market synopsis, classifications, applications, definitions, and industry chain structure. The report will be offering a significant insight while shedding light on the key players [ST.Jude, Deep Brain Innovations LLC, Aleva Neurotherapeutics, Stanford Health Care, Sapiens Healthcare, Beijing Pins Medical Co Ltd, Boston Scientific, Abbott
Potential Impact of COVID-19 on: Medical Digital Imaging Systems Market revenues …
The Medical Digital Imaging Systems Market report is intended to function as a supportive means to assess the Medical Digital Imaging Systems market ( https://bit.ly/3myHA8k ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the
Global Impact of COVID-19 on: Patient Engagement Software Market Development and …
The Patient Engagement Software market report provides an in-depth analysis of the global Patient Engagement Software market ( https://bit.ly/3kCFfsg ) , comprising the overall market synopsis, classifications, applications, definitions, and industry chain structure. The report will be offering a significant insight while shedding light on the key players [McKesson Corporation, Allscripts Healthcare Solutions, Phytel Inc, Athenahealth, Orion Health Ltd, Cerner Corporation, GetWellNetwork Inc, Lincor Solutions Ltd, YourCareUniverse Inc, WelVU, Get
Impact of COVID 19 on: TB Diagnostic Market Development and trends, COGS Analysi …
The TB Diagnostic Market report is intended to function as a supportive means to assess the TB Diagnostic market ( https://bit.ly/35H5vvl ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the clients in decision-making by
COVID-19 Recovery update: Pneumatic Tube Transport Systems Market revenues, COGS …
The Pneumatic Tube Transport Systems Market report is intended to function as a supportive means to assess the Pneumatic Tube Transport Systems market ( https://bit.ly/31PDNf0 ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the